Kenneth R. Shroyer Shroyer

Dr. Kenneth R. Shroyer Shroyer


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
LELuisa F Escobar-Hoyos
Luisa F Escobar-Hoyos
JYJie Yang
Jie Yang
JZJiawen Zhu
Jiawen Zhu
JCJulie-Ann Cavallo
Julie-Ann Cavallo
HZHaiyan Zhai
Haiyan Zhai
KSKenneth R. Shroyer Shroyer
Kenneth R. Shroyer Shroyer
Most previously described immunohistochemical markers of cervical high-grade squamous intraepithelial lesion (HSIL) and squamous cell carcinoma may help to improve diagnostic accuracy but have a minimal prognostic value. The goals of the current study were to identify and validate novel candidate biomarkers that could potentially improve diagnostic and prognostic accuracy for cervical HSIL and squamous cell carcinoma. Microdissected tissue sections from formalin-fixed paraffin-embedded normal ectocervical squamous mucosa, low-grade squamous intraepithelial lesion (LSIL), HSIL and squamous cell carcinoma sections were analyzed by mass spectrometry-based shotgun proteomics for biomarker discovery. The diagnostic specificity of candidate biomarkers was subsequently evaluated by immunohistochemical analysis of tissue microarrays. Among 1750 proteins identified by proteomic analyses, keratin 4 (KRT4) and keratin 17 (KRT17) showed reciprocal patterns of expression in the spectrum of cases ranging from normal ectocervical squamous mucosa to squamous cell carcinoma. Immunohistochemical studies confirmed that KRT4 expression was significantly decreased in squamous cell carcinoma compared with the other diagnostic categories. By contrast, KRT17 expression was significantly increased in HSIL and squamous cell carcinoma compared with normal ectocervical squamous mucosa and LSIL. KRT17 was also highly expressed in immature squamous metaplasia and in endocervical reserve cells but was generally not detected in mature squamous metaplasia. Furthermore, high levels of KRT17 expression were significantly associated with poor survival of squamous cell carcinoma patients (Hazard ratio=14.76, P=0.01). In summary, both KRT4 and KRT17 expressions are related to the histopathology of the cervical squamous mucosa; KRT17 is highly overexpressed in immature squamous metaplasia, in HSIL, and in squamous cell carcinoma and the level of KRT17 in squamous cell carcinoma may help to identify patients who are at greatest risk for cervical cancer mortality.

31 August 2015 in Cancer Research
Verified
Journal Article
Open access
PDF file
LELuisa F. Escobar-Hoyos
Luisa F. Escobar-Hoyos
RSRuchi Shah
Ruchi Shah
LRLucia Roa-Peña
Lucia Roa-Peña
EVElizabeth A. Vanner
Elizabeth A. Vanner
NNNilofar Najafian
Nilofar Najafian
KSKenneth R. Shroyer Shroyer
Kenneth R. Shroyer Shroyer
Keratins that are overexpressed selectively in human carcinomas may offer diagnostic and prognostic utility. In this study, we show that high expression of keratin-17 (K17) predicts poor outcome in patients with cervical cancer, at early or late stages of disease, surpassing in accuracy either tumor staging or loss of p27KIP1 as a negative prognostic marker in this setting. We investigated the mechanistic basis for the biologic impact of K17 through loss- and gain-of-function experiments in human cervix, breast, and pancreatic cancer cells. Specifically, we determined that K17 functions as an oncoprotein by regulating the subcellular localization and degradation of p27KIP1. We found that K17 was released from intermediate filaments and translocated into the nucleus via a nuclear localization signal (NLS), specific among keratins, where it bound p27KIP1 during G1 phase of the cell cycle. p27KIP1 lacks a nuclear export signal (NES) and requires an adaptor for CRM1 binding for nuclear export. In K17, we defined and validated a leucine-rich NES that mediated CRM1 binding for export. Cervical cancer cells expressing K17 mutations in its NLS or NES signals exhibited an increase in levels of nuclear p27KIP1, whereas cells expressing wild-type K17 exhibited a depletion in total endogenous p27KIP1. In clinical specimens of cervical cancer, we confirmed that the expressions of K17 and p27KIP1 were inversely correlated, both across tumors and within individual tumors. Overall, our findings establish that K17 functions specially among keratins as an oncoprotein by controlling the ability of p27KIP1 to influence cervical cancer pathogenesis. Cancer Res; 75(17); 3650–62. ©2015 AACR.

2 August 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LRLucia Roa-Peña
Lucia Roa-Peña
CLCindy V. Leiton
Cindy V. Leiton
SBSruthi Babu
Sruthi Babu
CPChun-Hao Pan
Chun-Hao Pan
EVElizabeth A. Vanner
Elizabeth A. Vanner
LELuisa F. Escobar-Hoyos
Luisa F. Escobar-Hoyos
Although the overall five-year survival of patients with pancreatic ductal adenocarcinoma (PDAC) is dismal, there are survival differences between cases with clinically and pathologically indistinguishable characteristics, suggesting that there are uncharacterized properties that drive tumor progression. Recent mRNA sequencing studies reported gene-expression signatures that define PDAC molecular subtypes that correlate with differences in survival. We previously identified Keratin 17 (K17) as a negative prognostic biomarker in other cancer types. Here, we set out to determine if K17 is as accurate as molecular subtyping of PDAC to identify patients with the shortest survival. K17 mRNA was analyzed in two independent PDAC cohorts for discovery (n = 124) and validation (n = 145). Immunohistochemical localization and scoring of K17 immunohistochemistry (IHC) was performed in a third independent cohort (n = 74). Kaplan-Meier and Cox proportional-hazard regression models were analyzed to determine cancer specific survival differences in low vs. high mRNA K17 expressing cases. We established that K17 expression in PDACs defines the most aggressive form of the disease. By using Cox proportional hazard ratio, we found that increased expression of K17 at the IHC level is also associated with decreased survival of PDAC patients. Additionally, within PDACs of advanced stage and negative surgical margins, K17 at both mRNA and IHC level is sufficient to identify the subgroup with the shortest survival. These results identify K17 as a novel negative prognostic biomarker that could inform patient management decisions.

1 January 2010 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
GBGalina I Botchkina
Galina I Botchkina
EZEdison S Zuniga
Edison S Zuniga
MDManisha Das
Manisha Das
YWYuan Wang
Yuan Wang
HWHaichao Wang
Haichao Wang
IOIwao Ojima
Iwao Ojima
Growing evidence suggests that the majority of tumors are organized hierarchically, comprising a population of tumor-initiating, or cancer stem cells (CSCs) responsible for tumor development, maintenance and resistance to drugs. Previously we have shown that the CD133high/CD44high fraction of colon cancer cells is different from their bulk counterparts at the functional, morphological and genomic levels. In contrast to the majority of colon cancer cells expressing moderate levels of CD133, CD44 and CD166, cells with a high combined expression of CD133 and CD44 possessed several characteristic stem cell features, including profound self-renewal capacity in vivo and in vitro, and the ability to give rise to different cell phenotypes. The present study was undertaken for two aims: a) to determine stem cell-related genomic characteristics of floating 3D multicellular spheroids induced by CD133high/CD44high colon cancer cells; and b) to evaluate CSC-specific alterations induced by new-generation taxoid SB-T-1214.

1 February 2008 in Human Pathology
Verified
Journal Article
Closed access
PDF file
JTJohn Thomison
John Thomison
LTLaurie K. Thomas
Laurie K. Thomas
KSKenneth R. Shroyer Shroyer
Kenneth R. Shroyer Shroyer

1 April 2017 in Human Pathology
Verified
Journal Article
Closed access
RMRoss D. Merkin
Ross D. Merkin
EVElizabeth A. Vanner
Elizabeth A. Vanner
JRJamie L Romeiser
Jamie L Romeiser
ASA. Laurie W. Shroyer
A. Laurie W. Shroyer
LELuisa F. Escobar-Hoyos
Luisa F. Escobar-Hoyos
KSKenneth R. Shroyer Shroyer
Kenneth R. Shroyer Shroyer